Grifols, unscathed by CSL’s problems, maintains distinct competitive edge
The Australian pharmaceutical company issued a profit warning on Monday for the 2026 financial year, but, judging by the robust demand for Grifols’ immunoglobulins, the issues stem from internal operational challenges rather than a general market downturn. Analysis by Renta 4 Australian firm CSL cut its guidance for the 2026 financial year on Monday, announced ~$5 billion in impairments (due to Vifor, a business it does not share with Grifols…
Read More
